The MedCity Moves Podcast is back with another episode. We dive into some of the executive appointments occurring in the healthcare sector over the past month — including new leaders at CommonSpirit, Centene and Athenahealth. We also discuss layoffs affecting the industry — such the recent rounds of job cuts at Cerner, Brightline and Scripps Health. For this episode’s guest interview, we hear from Lara Khouri, who recently became the new COO of Children’s Hospital Los Angeles. She joined CHLA in

Liquid biopsy test for cancer patients enables oncologists to identify targeted therapies and improve care BURLINGTON, N.C., May 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, has launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted therapy selection for patients with advanced or metastatic solid tumors. The test allows treating oncologists to evaluate circulating cell-free DNA (cfDNA) released by tumor cells and better manage the care o

NEW YORK, May 31, 2023 /PRNewswire/ -- Healthcare Trust, Inc. (Nasdaq: HTIA / HTIBP) ("HTI" or "the Company") announced today that, through its subsidiaries, the Company completed a $240 million commercial mortgage-backed security loan (the "Loan") encumbered by 62 medical office buildings ("MOB") across the United States. The Loan has a 10-year term and is interest-only at 6.453%. Proceeds from the Loan were used, in part, to repay $196 million and terminate the Company's credit facility with K

SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 9:30 AM ET in New York. The live and archived webcast of the presentation

ROCKVILLE, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 1:00 p.m. ET in New York City. Investors interested in arranging a meeting

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from June 7-9, 2023 in New York, NY. Gregory Oakes, Chief Executive Officer, and Fabio Cataldi, Chief Medical Officer, will provide a corporate update, including highlights of the NX-13 program and the recent

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 3:00 p.m. EDT. A live webcast of the presentation will be available on the Investors section of the Viracta w

HAMILTON, ON and BOSTON, May 31, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 04:00 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D. A live webcast of the event will be available on t

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 10:00 a.m. ET. The live webcast of the discussion will be available through the investor section of the company’s website

Exclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver diseasePreclinical and clinical evidence support ASK1 inhibition as a relevant therapeutic strategy in multi-system disorders such as Acute-on-Chronic Liver Failure (ACLF)First-in-Human study planned in the second half of 2024 to support a Proof-of-Concept study in ACLF patients as early as 2025No material impact on previously guided cash runway: company funding rem